Director Alpna Seth filed a Form 4 with the SEC on November 2, 2026, disclosing the acquisition of 2,750 shares of BIO-TECHNE Corp common stock on October 29, 2026, at no cost, along with the grant of new stock options.

Key Highlights

  • Shares acquired: Alpna Seth received 2,750 shares of common stock on October 29, 2026, at a price of $0.
  • Post-transaction holdings: Following the transaction, Seth directly holds 18,161 shares of BIO-TECHNE common stock.
  • New stock options: Seth was also granted 3,777 stock options (right to buy common stock) with an exercise price of $60.96, exercisable October 29, 2026, and expiring October 30, 2035.
  • Existing options: Seth holds six additional tranches of stock options with exercise prices ranging from $50.41 to $68.37, expiring between 2029 and 2034.
  • Filing party: The form was signed by Andrew Nick as Attorney-in-Fact for Alpna Seth pursuant to a previously filed Power of Attorney.
  • Exchange and ticker: BIO-TECHNE Corp is listed as NASDAQ:TECH in the filing.

Alpna Seth's October 2026 BIO-TECHNE Share and Option Award

According to the Form 4 filed on November 2, 2026, Alpna Seth, a director of BIO-TECHNE Corp (NASDAQ:TECH), acquired 2,750 shares of the company's common stock on October 29, 2026, through a transaction coded "A" (acquisition) at a reported price of $0. Following this transaction, Seth's direct beneficial ownership of BIO-TECHNE common stock stands at 18,161 shares, as disclosed in Table I of the filing.

In addition to the common stock acquisition, the filing reports that Seth received a new grant of 3,777 stock options (right to buy) with an exercise price of $60.96 per share. These options became exercisable on October 29, 2026, and are set to expire on October 30, 2035. The options are held directly, according to the filing.

Table II of the filing also lists six previously granted stock option tranches held by Seth, all directly owned. These range from 8,044 options with an exercise price of $50.41 (exercisable October 24, 2020, expiring October 24, 2029) to 3,511 options with an exercise price of $68.37 (exercisable October 24, 2025, expiring October 24, 2034). The filing was signed by Andrew Nick as Attorney-in-Fact for Alpna Seth pursuant to a Power of Attorney previously filed with the SEC.

What Was Disclosed

The filing reports director Alpna Seth's acquisition of 2,750 shares of BIO-TECHNE common stock at $0 on October 29, 2026, bringing direct holdings to 18,161 shares, alongside a new grant of 3,777 stock options at an exercise price of $60.96 expiring October 30, 2035.